Item no. |
CSB-AP003001HU-500 |
Manufacturer |
Cusabio
|
Amount |
500ug |
Quantity options |
1mg
10ug
100ug
250ug
50ug
500ug
|
Category |
|
Type |
Proteins Recombinant |
Format |
Lyophilized powder |
Specific against |
Human |
Purity |
>95% as determined by SDS-PAGE and HPLC. |
ECLASS 10.1 |
32160409 |
ECLASS 11.0 |
32160409 |
UNSPSC |
12352202 |
Available |
|
Classification |
Cytokine |
Subdivision |
Tumor Necrosis Factor |
Research Areas |
Immunology |
Uniprot NO. |
O00300 |
Uniprot Entry Name |
TR11B_HUMAN |
Gene Names |
TNFRSF11B, OCIF, OPG |
Source |
E.Coli |
Expression Region |
22-194aa |
Sequence |
ETFPPKYLHY DEETSHQLLC DKCPPGTYLK QH CTAKWKTV CAPCPDHYYT DSWHTSDECL YCSP VCKELQ YVKQECNRTH NRVCECKEGR YLEIEF CLKH RSCPPGFGVV QAGTPERNTV CKRCPDGF FS NETSSKAPCR KHTNCSVFGL LLTQKGNATH DNICSGNSES TQK |
Protein Description |
Partial |
Tag Info |
Tag-Free |
Mol. Weight |
19.7 kDa |
Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by neutralizing the stimulation of U937 cells is less than 10 ng/ml, corresponding to a specific activity of ? 1.0 x 105 IU/mg in the presence of 10 ng/mL soluble rHuRANKL (sRANKL). |
Purity |
>95% as determined by SDS-PAGE and HPLC. |
Endotoxin |
Less than 1.0 EU/ug as determined by LAL method. |
Storage Buffer |
0.2 um filtered 30 % acetonitrile, 0.1 % TFA , lyophilized |
Alias |
Osteoclastogenesis inhibitory factor, |
Relevance |
Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis. {ECO:0000269|PubMed:22664871, ECO:0000269|PubMed:9168977}. |
PubMed ID |
9108485; 9492069; 9688283; 14702039; 16421571; 15489334; 9571159; 15340161; 12110935; 9168977; 9603945; 9478964; 11505389; 22664871; 12189164 |
Function |
Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis. |
Involvement in disease |
Paget disease of bone 5, juvenile-onset (PDB5) |
Subcellular Location |
Secreted |
Tissue Specificity |
Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung. |
Paythway |
Osteoclastdifferentiation |
Tag Information |
Tag-Free |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.